Population Pharmacokinetics and Pharmacodynamics of Lampalizumab Administered Intravitreally to Patients with Geographic Atrophy

CPT: Pharmacometrics and Systems Pharmacology

Volumn 4, Issue 10, 2015, Pages 595-604

  Le, K N ^a   Gibiansky, L ^b   Van Lookeren Campagne, M ^a   Good, J ^a   Davancaze, T ^a   Loyet, K M ^a   Morimoto, A ^a   Strauss, E C ^a   Jin, J Y ^a  

^a GENENTECH INC   (United States)

^b QuantPharm LLC 49 Flints Grove Drive   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LAMPALIZUMAB;

ABSORPTION HALF-LIFE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EFFICACY; DRUG SAFETY; GEOGRAPHIC ATROPHY; HUMAN; IC50; LIMIT OF QUANTITATION; LOWER LIMIT OF QUANTITATION; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; PARTITION COEFFICIENT; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUASI STEADY STATE; RANDOMIZED CONTROLLED TRIAL; STUDY DESIGN; TARGET MEDIATED DRUG DISPOSITION; VITREOUS BODY;

EID: 84945435206     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12031     Document Type: Article

References (34)

1. Wong, W.L., et al,. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob. Health. 2, e106-116 (2014).
2. Sunness, J.S., et al,. Visual function abnormalities and prognosis in eyes with age-related geographic atrophy of the macula and good visual acuity. Ophthalmology. 104, 1677-1691 (1997).
3. Augood, C.A., et al,. Prevalence of age-related maculopathy in older Europeans: the European Eye Study (EUREYE). Arch. Ophthalmol. 124, 529-535 (2006).
4. Friedman, D.S., et al,. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564-572 (2004).
5. Rees, A., Zekite, A., Bunce, C., &, Patel, P.J., How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration? Eye (Lond). 28, 832-837 (2014).
6. Rees A., et al,. Definition of blindess given in: United Kingdom Department of Health. Certificate of vision impairment explanatory notes for consultant ophthalmologists and hospital eye clinic staff. < https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/213286/CVI-Explanatory-notes-in-DH-template.pdf >. Published 2013. Accessed November 10, 2014.
7. Lindblad, A.S., et al,. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch. Ophthalmol. 127, 1168-1174 (2009).
8. Katschke, K.J., Jr., et al,. Inhibiting alternative pathway complement activation by targeting the factor D exosite. J. Biol. Chem. 287, 12886-12892 (2012).
9. Tanhehco, E.J., et al,. The anti-factor D antibody, MAb 166-32, inhibits the alternative pathway of the human complement system. Transplant. Proc. 31, 2168-2171 (1999).
10. Do, D.V., et al,. A phase ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina. 34, 313-320 (2014).
11. Loyet, K.M., et al,. Complement inhibition in cynomolgus monkeys by anti-factor d antigen-binding fragment for the treatment of an advanced form of dry age-related macular degeneration. J. Pharmacol. Exp. Ther. 351, 527-537 (2014).
12. Avery, R.L., et al,. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD. Br. J. Ophthalmol. 98, 1636-1641 (2014).
13. Bakri, S.J., Snyder, M.R., Reid, J.M., Pulido, J.S., Ezzat, M.K., &, Singh, R.J., Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology 114, 2179-2182 (2007).
14. Bakri, S.J., Snyder, M.R., Reid, J.M., Pulido, J.S., &, Singh, R.J., Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114, 855-859 (2007).
15. Gaudreault, J., et al,. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits. Retina. 27, 1260-1266 (2007).
16. Gaudreault, J., Fei, D., Rusit, J., Suboc, P., &, Shiu, V., Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest. Ophthalmol. Vis. Sci. 46, 726-733 (2005).
17. Krohne, T.U., Eter, N., Holz, F.G., &, Meyer, C.H., Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. Am. J. Ophthalmol. 146, 508-512 (2008).
18. Krohne, T.U., Liu, Z., Holz, F.G., &, Meyer, C.H., Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am. J. Ophthalmol. 154, 682-686 e682 (2012).
19. Xu, L., et al,. Pharmacokinetics of ranibizumab in patients with neovascular age-related macular degeneration: a population approach. Invest. Ophthalmol. Vis. Sci. 54, 1616-1624 (2013).
20. Beal, S.L., Sheiner, L.B., Boeckmann, A.J., &, Bauer, R.J., NONMEM Users Guides. 1989-2013 (Icon Development Solutions, Ellicott City, MD, 2013).
21. Gibiansky, L., Gibiansky, E., &, Bauer, R., Comparison of Nonmem 7.2 estimation methods and parallel processing efficiency on a target-mediated drug disposition model. J. Pharmacokinet. Pharmacodyn. 39, 17-35 (2012).
22. Gibiansky, L., Gibiansky, E., Kakkar, T., &, Ma, P., Approximations of the target-mediated drug disposition model and identifiability of model parameters. J. Pharmacokinet. Pharmacodyn. 35, 573-591 (2008).
23. Xu, Z.H., et al,. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int. J. Clin. Pharmacol. Ther. 48, 596-607 (2010).
24. Ng, C.M., Stefanich, E., Anand, B.S., Fielder, P.J., &, Vaickus, L., Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm. Res. 23, 95-103 (2006).
25. Ng, C.M., Joshi, A., Dedrick, R.L., Garovoy, M.R., &, Bauer, R.J., Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm. Res. 22, 1088-1100 (2005).
26. Avery, R.L., Le, K., Lu, T, Sternberg, G, Visich, J., Visual acuity response as a function of the affinity and vitreous half-life of intravitreally-administered anti-VEGF agents. Presented at the ASRS 30th Annual Meeting: August 28, 2012, Aria Resort, Las Vegas, NV.
27. Pascual, M., Steiger, G., Estreicher, J., Macon, K., Volanakis, J.E., &, Schifferli, J.A., Metabolism of complement factor D in renal failure. Kidney Int. 34, 529-536 (1988).
28. Anderson, D.H., et al,. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res. 29, 95-112 (2010).
29. Hayashi, N., Tsukamoto, Y., Sallas, W.M., &, Lowe, P.J., A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br. J. Clin. Pharmacol. 63, 548-561 (2007).
30. Lobo, E.D., Hansen, R.J., &, Balthasar, J.P., Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93, 2645-2668 (2004).
31. Renard, C., Grene-Lerouge, N., Beau, N., Baud, F., &, Scherrmann, J.M., Pharmacokinetics of digoxin-specific Fab: effects of decreased renal function and age. Br. J. Clin. Pharmacol. 44, 135-138 (1997).
32. Wochner, R.D., Strober, W., &, Waldmann, T.A., The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J. Exp. Med. 126, 207-221 (1967).
33. Wang, J., McLeod, D., Henson, D.B., &, Bishop, P.N., Age-dependent changes in the basal retinovitreous adhesion. Invest. Ophthalmol. Vis. Sci. 44, 1793-1800 (2003).
34. Los, L.I., van der Worp, R.J., van Luyn, M.J., &, Hooymans, J.M., Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. Invest. Ophthalmol. Vis. Sci. 44, 2828-2833 (2003).